2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-165407
    Neltenexine 99453-84-6
    Neltenexine, a mucolytic agent, is an Elastase inhibitor. Neltenexine diminishes anion secretion in in bronchial epithelial cells by inhibiting the Cl− and HCO3- uptake via Na/K/2Cl++− and Na+/HCO3- cotransporter without blockade of the CFTR channel, and also diminishes anion secretion via stimulation of Cl−/HCO3- exchanger. Neltenexine significantly prevents pulmonary emphysema with a reduction of alveolar deformation in rat models induced by Elastase. Neltenexine can be used for lung diseases such as chronic obstructive pulmonary disease (COPD) research.
    Neltenexine
  • HY-165441
    R-836 94415-03-9 98%
    R-836 is an orally active bronchodilator. R-836 is also a weak phosphodiesterase inhibitor. R-836 can reduce bronchoconstriction caused by antigens or platelet-activating factor. R-836 prevents asphyxiation or dyspnea.
    R-836
  • HY-165453
    VUF14480 1605304-31-1
    VUF14480 is a partial agonist of histamine H4 (hH4) receptor-mediated G protein signalling and β-arrestin2 recruitment. VUF14480 binds covalently to hH4 receptor (pKi: 6.3 for hH4-WT receptor). VUF14480 partially induces hH4 receptor-mediated G protein activation and β-arrestin2 recruitment. VUF14480 can be used in the research of inflammatory diseases.
    VUF14480
  • HY-165459
    KJM429 401907-57-1
    KJM429 (MK-056) is a high-affinity ligand for the rat vanilloid receptor rTRPV1 (Ki=30-63 nM) with a unique dual regulatory function. KJM429 acts as a competitive antagonist to inhibit TRPV1 receptor activation induced by Capsaicin (HY-10448), resiniferatoxin, thermal stimulation and weak acid (pH 6.0), and switches to a TRPV1 agonist under strong acid conditions (pH<5.5). KJM429 effectively blocks calcium influx induced by Capsaicin and partial thermal stimulation, and triggers calcium uptake under low pH conditions, with minimal effects on non-TRPV1-mediated calcium signaling. KJM429 can be used for research on the mechanisms of pain-related diseases such as postherpetic neuralgia, diabetic neuropathy, cluster headache, osteoarthritis and pruritus.
    KJM429
  • HY-165484
    AVP-13358 459805-03-9 98%
    AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses.
    AVP-13358
  • HY-165489
    AU-006 220831-12-9
    AU-006 is an orally active inhibitor of gastric acid secretion, with anti-ulcer effects. AU-006 does not rely on NO and mucus regulation. AU-006 significantly prevents 95% of gastric mucosal damage caused by ethanol and has broad-spectrum protective effects against chemical corrosive damage. AU-006 can be used for research on gastric ulcers.
    .
    AU-006
  • HY-165492
    Opc 14117 103233-65-4
    OPC-14117 is an orally active superoxide radical scavenger that can cross the blood-brain barrier. OPC-14117 inhibits the oxidative stress cascade reaction, significantly reducing the increase in tissue osmotic pressure and alleviating brain edema in the brain contusion model. OPC-14117 blocks the NF-κB-dependent apoptotic pathway in the striatum neuron apoptosis model induced by Quinolinic acid (HY-100807). OPC-14117 can reduce the necrotic volume, protect hippocampal CA3 neurons and restore cognitive function. OPC-14117 can be used to study secondary brain injury and improve neurological prognosis.
    Opc 14117
  • HY-165528
    Histamine glutarimide 1464897-15-1
    Histamine glutarimide (XC8) is an orally active anti-asthma agent. Histamine glutarimide blocks the maturation of chemokines (CCL2, CCL7, CCL8, CCL13) and inhibits the migration of eosinophils and the degranulation of mast cells. In asthma models induced by carrageenan and rat ovalbumin, Histamine glutarimide can reduce airway resistance and the count of eosinophils in bronchoalveolar lavage fluid. Histamine glutarimide can be used in asthma research.
    Histamine glutarimide
  • HY-165557
    GSK1370319A 1001389-31-6 98%
    GSK1370319A is a human P2X7 receptor inhibitor with an IC50 of 474 nM and a Ki of 176 nM. GSK1370319A inhibits the production of IL-1β, reduces the generation of reactive oxygen species (ROS), and increases the survival rate of macrophages. GSK1370319A can be used for the research of inflammatory bowel disease.
    GSK1370319A
  • HY-165564
    SM-8849 113759-19-6 98%
    SM-8849 is a thiazole derivative with anti-arthritis activity. SM-8849 specifically targets and inactivates T cells involved in delayed-type hypersensitivity (DTH) reactions, thereby inhibiting the core immunopathological process of arthritis, but has little effect on the humoral immune process such as antibody production. In a mouse arthritis model induced by Type II Collagen (HY-NP003), SM-8849 significantly alleviated clinical symptoms, reduced bone destruction and joint damage. SM-8849 can be used for the study of autoimmune diseases such as rheumatoid arthritis.
    SM-8849
  • HY-16561G
    Resveratrol (GMP) 501-36-0 98%
    Resveratrol (GMP) is Resveratrol (HY-16561) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
    Resveratrol (GMP)
  • HY-16569B
    Colchicine,suitable for plant cell culture 64-86-8 98%
    Colchicine,suitable for plant cell culture, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine,suitable for plant cell culture can be used for plant cell culture.
    Colchicine,suitable for plant cell culture
  • HY-167141
    AY 29315 114394-28-4
    AY 29315 is a selective and orally active histamine H2-receptor antagonist. AY 29315 can inhibit astric acid secretion and shows antiulcer activity. AY 29315 can be used for the research of gastric ulcer.
    AY 29315
  • HY-167153
    PNA5 2186644-51-7
    PNA5 is a novel, blood-brain barrier permeable glycosylated angiotensin-(1-7) peptide and MasR agonist. PNA5 inhibits IL-7, increases IL-10. PNA5 inhibits ROS generation, decreases Iba-1 expression. PNA5 exhibits sustained cognitive protective effects. PNA5 rescues blunted cerebral functional hyperemia. PNA5 can be used in the research of inflammation-related brain diseases.
    PNA5
  • HY-16764A
    Acorafloxacin hydrochloride 1001162-01-1 98%
    Acorafloxacin hydrochloride (JNJ-Q2 hydrochloride) is a broad-spectrum fluoroquinolone anti-bacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Acorafloxacin hydrochloride is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value. Acorafloxacin hydrochloride has potential for study of methicillin-resistant Staphylococcus aureus (MRSA) infections.
    Acorafloxacin hydrochloride
  • HY-167676
    Cofpropamine 80539-94-2 98%
    Cofpropamine, a caffeine derivative that inhibits polyadenylation, enhances the inhibitory effect of cyclophosphamide (HY-17420) in rat adjuvant arthritis and mouse collagen arthritis models.
    Cofpropamine
  • HY-167698
    Dibenamine 51-50-3
    Dibenamine is an alpha-adrenergic antagonist that exhibits the ability to block both basal and histamine-stimulated gastric acid secretion, making it therapeutically relevant in conditions involving excessive gastric acid production.
    Dibenamine
  • HY-167711
    Sirtuin modulator 9 863589-28-0 98%
    Sirtuin modulator 9 (Compound 214) is a sirtuin-modulating compound that may be used to increase lifespan of cells and in diseases related to aging, inflammation and cancer as well as diseases that would benefit from increased mitochondrial activity.
    Sirtuin modulator 9
  • HY-167715
    Traxanox 58712-69-9 98%
    Traxanox is an orally available diuretic that enhances phagocytosis of yeast granules by mouse peritoneal macrophages and rat peritoneal polymorphonuclear leukocytes in vitro. Traxanox inhibits IgE-mediated histamine release and cyclic AMP phosphodiesterase activity.Traxanox exhibits anti-inflammatory activity, as it inhibits the anaphylactoid reaction and reduces pleural fluid accumulation in experimental models of inflammation. Traxanox also demonstrates a synergistic effect when combined with hydrocortisone or indomethacin in suppressing adjuvant arthritis in rats.
    Traxanox
  • HY-167719
    Dersalazine 188913-58-8 98%
    Dersalazine (UR-12746 free base) is an inhibitor of platelet-activating factor, exhibiting intestinal anti-inflammatory activity and potential efficacy in treating ulcerative colitis.
    Dersalazine
Cat. No. Product Name / Synonyms Application Reactivity